vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
vTv Therapeutics (Nasdaq: VTVT) announced on October 9, 2025 the appointment of Alfonso Galderisi, Mark Evans, Chantal Mathieu, and Klara Klein to its Scientific Advisory Board. The SAB, composed of international leaders in endocrinology, clinical trial design, and regulatory science, will advise on the development of cadisegliatin, an oral adjunctive therapy currently being investigated in Phase 3 clinical trials for type 1 diabetes (T1D).
The board complements existing members, including John Buse and Alexander Fleming, to provide input on clinical trial planning, study design, endpoints, regulatory strategy, and target product profile for cadisegliatin.
vTv Therapeutics (Nasdaq: VTVT) ha annunciato il 9 ottobre 2025 la nomina di Alfonso Galderisi, Mark Evans, Chantal Mathieu e Klara Klein al suo Scientific Advisory Board. Il SAB, composto da leader internazionali in endocrinologia, progettazione di trial clinici e scienza regolatoria, fornirà consulenza sullo sviluppo di cadisegliatin, una terapia adiuvante orale attualmente in fase di prova clinica di fase 3 per il diabete di tipo 1 (DT1).
Il consiglio integra i membri esistenti, tra cui John Buse e Alexander Fleming, per offrire contributi sulla pianificazione degli studi clinici, sul design degli studi, sugli endpoint, sulla strategia regolatoria e sul profilo di prodotto target per cadisegliatin.
vTv Therapeutics (Nasdaq: VTVT) anunció el 9 de octubre de 2025 el nombramiento de Alfonso Galderisi, Mark Evans, Chantal Mathieu y Klara Klein en su Junta Asesora Científica. El SAB, compuesto por líderes internacionales en endocrinología, diseño de ensayos clínicos y ciencia regulatoria, asesorará sobre el desarrollo de cadisegliatin, una terapia oral adyuvante actualmente en ensayos clínicos de fase 3 para la diabetes tipo 1 (DT1).
La junta complementa a los miembros existentes, entre ellos John Buse y Alexander Fleming, para aportar ideas sobre la planificación de ensayos, el diseño del estudio, los endpoints, la estrategia regulatoria y el perfil de producto objetivo para cadisegliatin.
vTv Therapeutics (나스닥: VTVT)은 2025년 10월 9일 Alfonso Galderisi, Mark Evans, Chantal Mathieu, Klara Klein를 과학 자문위원회(SAB)에 임명했다고 발표했습니다. SAB는 내분비학, 임상시험 설계 및 규제 과학의 국제적 리더들로 구성되어 있으며 cadisegliatin의 개발에 대해 자문할 예정이며, 이는 현재 당뇨병 1형(T1D)에 대한 3상 임상시험에서 조사 중인 경구 보조 요법입니다.
이 위원회는 John Buse와 Alexander Fleming을 포함한 기존 위원들을 보완하여 cadisegliatin의 임상시험 계획, 연구 설계, 엔드포인트, 규제 전략 및 목표 제품 프로파일에 대한 의견을 제공합니다.
vTv Therapeutics (Nasdaq: VTVT) a annoncé le 9 octobre 2025 la nomination d'Alfonso Galderisi, Mark Evans, Chantal Mathieu et Klara Klein au sein de son Scientific Advisory Board. Le SAB, composé de leaders internationaux en endocrinologie, conception d'essais cliniques et sciences réglementaires, conseillera sur le développement de cadisegliatin, une thérapie adjuvante orale actuellement à l'étude dans des essais cliniques de phase 3 pour le diabète de type 1 (DT1).
Le conseil complète les membres existants, y compris John Buse et Alexander Fleming, afin de fournir des contributions sur la planification des essais cliniques, la conception des études, les endpoints, la stratégie réglementaire et le profil de produit cible pour cadisegliatin.
vTv Therapeutics (Nasdaq: VTVT) gab am 9. Oktober 2025 die Bestellung von Alfonso Galderisi, Mark Evans, Chantal Mathieu und Klara Klein in den Wissenschaftlichen Beirat bekannt. Der SAB, zusammengesetzt aus internationalen Führungskräften in Endokrinologie, Studiendesign und Regulierung Sciences, wird Ratschläge zur Entwicklung von cadisegliatin geben, einer oralen additiven Therapie, die derzeit in Phase-3-Studien für Typ-1-Diabetes (T1D) untersucht wird.
Der Beirat ergänzt die bestehenden Mitglieder, darunter John Buse und Alexander Fleming, um Beiträge zur Planung klinischer Studien, Studiendesign, Endpunkte, regulatorischen Strategie und dem Zielprodukten-Profil für cadisegliatin zu liefern.
vTv Therapeutics (ناسداك: VTVT) أعلن في 9 أكتوبر 2025 عن تعيين ألفونسو غالدريسي، مارك إيفانز، شانتال ماثيو وكلارا كلاين في مجلسه الاستشاري العلمي. يتكوّن SAB من روّاد دوليين في الغدد الصماء وتصميم التجارب السريرية والعلوم التنظيمية، وسيقدّم المشورة بشأن تطوير cadisegliatin، علاج مساعد فموي قيد التحقيق حاليًا في تجارب المرحلة 3 لمرض السكري من النوع 1 (DT1).
يكمل المجلس الأعضاء الحاليين، بمن فيهم جون بوث وآلكسندر فليمنغ، لتقديم مدخلات حول تخطيط التجارب السريرية وتصميم الدراسات ونقاط النهاية والاستراتيجية التنظيمية وملف المنتج المستهدف لـcadisegliatin.
vTv Therapeutics (纳斯达克: VTVT) 于 2025年10月9日 宣布任命阿方索·加德里西、马克·埃文斯、昌塔尔·马修和克拉拉·克莱因加入其科学顾问委员会。该科学顾问委员会由在内分泌学、临床试验设计和监管科学领域的国际领袖组成，将为 cadisegliatin 的开发提供咨询，这是一种口服辅助治疗，当前正在进行针对 1型糖尿病（T1D） 的 3期临床试验 的研究。
该委员会补充现有成员，包括约翰·布斯和亚历山大·弗莱明，为 cadisegliatin 在临床试验规划、研究设计、终点、监管策略和目标产品特征方面提供意见。
- Initiation of Phase 3 clinical trials for cadisegliatin
- Added SAB members with pediatric and adult T1D expertise
- SAB includes a former FDA reviewer with regulatory strategy experience
- Multiple SAB members serve as active clinical trial investigators
- None.
Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials
HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board (SAB). The SAB, composed of internationally recognized leaders in endocrinology, diabetes research, clinical trial design, and regulatory science, will continue providing strategic guidance on the development of cadisegliatin, which is currently being investigated in Phase 3 clinical trials as an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D).
“We are honored to welcome such a distinguished group of clinicians and scientists to vTv’s Scientific Advisory Board,” said Paul Sekhri, Chairman, President, and CEO of vTv Therapeutics. “Their collective experience in diabetes care, clinical research, and regulatory engagement will be invaluable as we advance cadisegliatin and work to bring meaningful innovation to people living with type 1 diabetes. We also thank those past members of our SAB whose contributions have helped us immeasurably over the past several years.”
The members of the Scientific Advisory Board include:
- John Buse, MD, PhD is a Professor of Medicine at the University of North Carolina at Chapel Hill and former President of the American Diabetes Association. He brings expertise in clinical trial design, diabetes outcomes, and therapeutic guidelines.
- Alfonso Galderisi, MD, PhD is a pediatric endocrinologist and physician-scientist (Associate Professor) at Yale University who specializes in the metabolic physiology of preclinical type 1 diabetes.
- Mark Evans, MD is a Professor of Diabetic Medicine at the University of Cambridge, U.K. He is renowned for his work on hypoglycemia and contributions to the Hypo-RESOLVE consortium.
- Chantal Mathieu, MD, PhD is a Professor of Medicine at the University of Leuven, Belgium and global expert in diabetes care and guidelines (EASD, EUDF).
- Alexander (Zan) Fleming, MD is Executive Chairman of Kinexum. At the FDA, Dr. Fleming was responsible for therapeutic review of diabetes and other metabolic and endocrine disorders and is a recognized expert in regulatory strategy.
- Klara Klein, MD, PhD is an Assistant Professor at the University of North Carolina at Chapel Hill. She serves as a Principal Investigator for multiple vTv clinical trials and is an experienced investigator in type 1 diabetes therapeutics.
The SAB will regularly provide input on clinical trial planning, study design, endpoints, regulatory strategy, and the development of the target product profile for cadisegliatin.
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated as a potential first-in-class oral adjunctive treatment to insulin for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin, which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage.
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral liver-selective glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
Forward-Looking Statements
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the timing of our clinical trials, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396‑8551
caren.begun@tmstrat.com
FAQ
Who did vTv Therapeutics (VTVT) add to its Scientific Advisory Board on October 9, 2025?
What will the new SAB members advise on for cadisegliatin (VTVT)?
What is the development status of cadisegliatin as of October 9, 2025 for VTVT?
Does the SAB include experts with regulatory experience for VTVT’s cadisegliatin program?
Which existing advisors remain on vTv’s SAB supporting cadisegliatin development?
Where will vTv provide future updates about cadisegliatin clinical development and SAB activities?
